{"id":"aga2115","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AGA2115 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell proliferation and survival. This inhibition leads to anti-tumor effects. The exact mechanism of action is not fully understood.","oneSentence":"AGA2115 is a small molecule drug that targets the PI3K/AKT/mTOR pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:12.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT07062588","phase":"PHASE2","title":"Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)","status":"RECRUITING","sponsor":"Angitia Incorporated Limited","startDate":"2025-12-12","conditions":"Osteogenesis Imperfecta (OI)","enrollment":80},{"nctId":"NCT06086613","phase":"PHASE1","title":"A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Angitia Incorporated Limited","startDate":"2023-10-03","conditions":"Osteogenesis Imperfecta","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGA2115","genericName":"AGA2115","companyName":"Angitia Incorporated Limited","companyId":"angitia-incorporated-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGA2115 is a small molecule drug that targets the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}